• OS Therapies posted a net loss of USD 10.4 million for the three months ended March 31, 2026, widening from USD 3.9 million a year earlier as the operating loss grew to USD 10.17 million from USD 5 million.
• Research and development expense climbed to USD 7.35 million from USD 1.31 million, while general and administrative expense fell to USD 2.82 million from USD 3.69 million.
• Other expense totaled USD 228,893 versus other income of USD 1.12 million, reflecting USD 75,344 of interest expense and USD 153,594 of non-operating expense; there was no revenue in either period.
• Cash rose to about USD 0.9 million at March 31, 2026 from about USD 0.3 million at year-end, with USD 5.21 million of cash provided by financing activities during the quarter.
• Net proceeds included about USD 3.5 million from a January warrant exercise inducement and exchange offer and USD 2 million in gross proceeds from a March bridge financing; the company also completed an April registered direct offering with about USD 4.7 million in net proceeds.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OS Therapies Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-058070), on May 18, 2026, and is solely responsible for the information contained therein.